MEK-话题@MedSci

#MEK#

68篇内容 | 2189人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1943890, encodeId=a0cd194389059, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Am J Ophthalmol Case Rep：内皮角膜移植术-DMEK, objectType=article, longId=150076, objectId=776f1500e6fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=776f1500e6fa, replyNumber=0, likeNumber=46, createdTime=2019-01-28, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=776f1500e6fa, moduleTitle=Am J Ophthalmol Case Rep：内皮角膜移植术-DMEK, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=776f1500e6fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943889, encodeId=04291943889fb, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Braftovi/Mektovi联合欧洲获批用于治疗BRAFV600突变的不可切除或转移性黑色素瘤, objectType=article, longId=149597, objectId=26f714959eaf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26f714959eaf, replyNumber=0, likeNumber=58, createdTime=2019-02-14, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26f714959eaf, moduleTitle=Braftovi/Mektovi联合欧洲获批用于治疗BRAFV600突变的不可切除或转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26f714959eaf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943897, encodeId=90d0194389e32, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Sci Transl Med:KRAS突变型肺癌或喜迎MEK抑制剂联合用药, objectType=article, longId=162939, objectId=156a1629396a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=156a1629396a, replyNumber=0, likeNumber=74, createdTime=2019-09-01, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=156a1629396a, moduleTitle=Sci Transl Med:KRAS突变型肺癌或喜迎MEK抑制剂联合用药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=156a1629396a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943903, encodeId=ea84194390364, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=BRAF、EGFR、MEK，三靶向无化疗方案或成为BRAF V600E突变型mCRC新标准治疗, objectType=article, longId=175233, objectId=c5631e5233ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5631e5233ba, replyNumber=0, likeNumber=66, createdTime=2019-10-08, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5631e5233ba, moduleTitle=BRAF、EGFR、MEK，三靶向无化疗方案或成为BRAF V600E突变型mCRC新标准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5631e5233ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943891, encodeId=095e19438911e, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=NICE推荐BRAF激酶抑制剂与MEK抑制剂联合治疗BRAF V600突变的黑素瘤患者, objectType=article, longId=158891, objectId=8a5b15889101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a5b15889101, replyNumber=0, likeNumber=88, createdTime=2019-12-02, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a5b15889101, moduleTitle=NICE推荐BRAF激酶抑制剂与MEK抑制剂联合治疗BRAF V600突变的黑素瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a5b15889101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943887, encodeId=0e16194388ed3, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=EMA授予AZ和MSD公司MEK抑制剂孤儿药资格用于治疗1型神经纤维瘤, objectType=article, longId=145835, objectId=24c4145835bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24c4145835bc, replyNumber=0, likeNumber=74, createdTime=2019-01-14, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24c4145835bc, moduleTitle=EMA授予AZ和MSD公司MEK抑制剂孤儿药资格用于治疗1型神经纤维瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24c4145835bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943899, encodeId=e8ec194389911, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Phytomedicine：Dihydrosanguinarine通过调节mut-p53 / WT-p53和Ras/Raf/Mek/Erk通路抑制胰, objectType=article, longId=163086, objectId=683416308678, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=683416308678, replyNumber=0, likeNumber=51, createdTime=2020-03-09, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=683416308678, moduleTitle=Phytomedicine：Dihydrosanguinarine通过调节mut-p53 / WT-p53和Ras/Raf/Mek/Erk通路抑制胰, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=683416308678)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943892, encodeId=7816194389285, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=2019年美国皮肤病学会（AAD）年会：Bermekimab治疗特应性皮炎的II期临床试验取得突破性成果, objectType=article, longId=161551, objectId=9ed316155121, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ed316155121, replyNumber=0, likeNumber=0, createdTime=2019-11-12, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ed316155121, moduleTitle=2019年美国皮肤病学会（AAD）年会：Bermekimab治疗特应性皮炎的II期临床试验取得突破性成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ed316155121)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943900, encodeId=3b6519439006a, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=MEK抑制剂Selumetinib获得FDA突破疗法指定治疗丛状神经纤维瘤, objectType=article, longId=163506, objectId=9a621635067e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a621635067e, replyNumber=0, likeNumber=79, createdTime=2020-02-23, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a621635067e, moduleTitle=MEK抑制剂Selumetinib获得FDA突破疗法指定治疗丛状神经纤维瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a621635067e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943894, encodeId=26f019438945d, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=美国皮肤病学会报告：抗白细胞介素-1α抑制剂Bermekimab可迅速解决瘙痒症，有效治疗中度至重度难治性特应性皮炎, objectType=article, longId=162015, objectId=2f1516201561, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f1516201561, replyNumber=0, likeNumber=75, createdTime=2019-09-30, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f1516201561, moduleTitle=美国皮肤病学会报告：抗白细胞介素-1α抑制剂Bermekimab可迅速解决瘙痒症，有效治疗中度至重度难治性特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f1516201561)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943884, encodeId=7894194388490, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Lancet Oncol：新的BRAF/MEK联合抑制方案用于BRAF突变型黑色素瘤, objectType=article, longId=134563, objectId=3e681345639b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e681345639b, replyNumber=0, likeNumber=0, createdTime=2019-02-14, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e681345639b, moduleTitle=Lancet Oncol：新的BRAF/MEK联合抑制方案用于BRAF突变型黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e681345639b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943886, encodeId=1af619438866f, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Braftovi/Mektovi联合在美国获批用于BRAF突变转移性黑素瘤, objectType=article, longId=141927, objectId=83be14192e7c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83be14192e7c, replyNumber=0, likeNumber=78, createdTime=2019-02-14, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83be14192e7c, moduleTitle=Braftovi/Mektovi联合在美国获批用于BRAF突变转移性黑素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83be14192e7c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943882, encodeId=04761943882d2, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=EUR J Cancer：657例黑色素瘤患者NRAS的增益分析并评估其对MEK抑制剂的敏感性, objectType=article, longId=124480, objectId=bca6124480a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bca6124480a4, replyNumber=0, likeNumber=68, createdTime=2018-04-10, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bca6124480a4, moduleTitle=EUR J Cancer：657例黑色素瘤患者NRAS的增益分析并评估其对MEK抑制剂的敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bca6124480a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943881, encodeId=ae90194388164, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Ann Rheum Dis：bimekizumab在银屑病关节炎中的双重IL-17A和IL-17F中和, objectType=article, longId=124471, objectId=c0bc1244e185, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0bc1244e185, replyNumber=0, likeNumber=85, createdTime=2018-11-30, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0bc1244e185, moduleTitle=Ann Rheum Dis：bimekizumab在银屑病关节炎中的双重IL-17A和IL-17F中和, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0bc1244e185)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943888, encodeId=0e991943888ff, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=NICE支持Tafinlar与Mekinist的组合治疗晚期黑色素瘤, objectType=article, longId=149047, objectId=197214904e64, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=197214904e64, replyNumber=0, likeNumber=76, createdTime=2019-08-08, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=197214904e64, moduleTitle=NICE支持Tafinlar与Mekinist的组合治疗晚期黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=197214904e64)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943885, encodeId=2cb31943885c3, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=诺华BRAF抑制剂与MEK抑制剂获FDA批准联合靶向治疗黑色素瘤, objectType=article, longId=137007, objectId=d64a13e007c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d64a13e007c3, replyNumber=0, likeNumber=63, createdTime=2018-11-14, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d64a13e007c3, moduleTitle=诺华BRAF抑制剂与MEK抑制剂获FDA批准联合靶向治疗黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d64a13e007c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943883, encodeId=4d281943883da, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=EUR J Cancer：BRAF / MEK抑制剂的使用会产生脱髓鞘性多发性神经根神经病变, objectType=article, longId=125006, objectId=5ee4125006c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ee4125006c9, replyNumber=0, likeNumber=70, createdTime=2018-01-09, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ee4125006c9, moduleTitle=EUR J Cancer：BRAF / MEK抑制剂的使用会产生脱髓鞘性多发性神经根神经病变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ee4125006c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943880, encodeId=fa631943880d3, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Clin Cancer Res：AZD9291联合MEK抑制剂克服包含C797S的获得性耐药, objectType=article, longId=115437, objectId=65d511543e88, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65d511543e88, replyNumber=0, likeNumber=105, createdTime=2018-02-09, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65d511543e88, moduleTitle=Clin Cancer Res：AZD9291联合MEK抑制剂克服包含C797S的获得性耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65d511543e88)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943879, encodeId=99a119438e9c6, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Clin Cancer Res：MEK抑制剂单独或联合mTOR抑制剂对头颈部鳞状细胞癌的抗肿瘤作用, objectType=article, longId=50869, objectId=694b508695d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=694b508695d, replyNumber=0, likeNumber=79, createdTime=2016-02-04, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=694b508695d, moduleTitle=Clin Cancer Res：MEK抑制剂单独或联合mTOR抑制剂对头颈部鳞状细胞癌的抗肿瘤作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=694b508695d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943878, encodeId=316819438e8ba, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Ann Oncol：MEK抑制剂trametinib对KRAS突变的非小细胞肺癌的II期临床研究, objectType=article, longId=47689, objectId=936f4e689f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=936f4e689f6, replyNumber=0, likeNumber=90, createdTime=2015-08-01, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=936f4e689f6, moduleTitle=Ann Oncol：MEK抑制剂trametinib对KRAS突变的非小细胞肺癌的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=936f4e689f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

MEK

2020-05-29

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Am J Ophthalmol Case Rep：内皮角膜移植术-DMEK

2019-01-28

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Braftovi/Mektovi联合欧洲获批用于治疗BRAFV600突变的不可切除或转移性黑色素瘤

2019-02-14

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Sci Transl Med:KRAS突变型肺癌或喜迎MEK抑制剂联合用药

2019-09-01

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

BRAF、EGFR、MEK，三靶向无化疗方案或成为BRAF V600E突变型mCRC新标准治疗

2019-10-08

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

NICE推荐BRAF激酶抑制剂与MEK抑制剂联合治疗BRAF V600突变的黑素瘤患者

2019-12-02

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

EMA授予AZ和MSD公司MEK抑制剂孤儿药资格用于治疗1型神经纤维瘤

2019-01-14

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Phytomedicine：Dihydrosanguinarine通过调节mut-p53 / WT-p53和Ras/Raf/Mek/Erk通路抑制胰

2020-03-09

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

2019年美国皮肤病学会（AAD）年会：Bermekimab治疗特应性皮炎的II期临床试验取得突破性成果

2019-11-12

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

MEK抑制剂Selumetinib获得FDA突破疗法指定治疗丛状神经纤维瘤

2020-02-23

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

美国皮肤病学会报告：抗白细胞介素-1α抑制剂Bermekimab可迅速解决瘙痒症，有效治疗中度至重度难治性特应性皮炎

2019-09-30

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Lancet Oncol：新的BRAF/MEK联合抑制方案用于BRAF突变型黑色素瘤

2019-02-14

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Braftovi/Mektovi联合在美国获批用于BRAF突变转移性黑素瘤

2019-02-14

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

EUR J Cancer：657例黑色素瘤患者NRAS的增益分析并评估其对MEK抑制剂的敏感性

2018-04-10

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Ann Rheum Dis：bimekizumab在银屑病关节炎中的双重IL-17A和IL-17F中和

2018-11-30

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

NICE支持Tafinlar与Mekinist的组合治疗晚期黑色素瘤

2019-08-08

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

诺华BRAF抑制剂与MEK抑制剂获FDA批准联合靶向治疗黑色素瘤

2018-11-14

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

EUR J Cancer：BRAF / MEK抑制剂的使用会产生脱髓鞘性多发性神经根神经病变

2018-01-09

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Clin Cancer Res：AZD9291联合MEK抑制剂克服包含C797S的获得性耐药

2018-02-09

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Clin Cancer Res：MEK抑制剂单独或联合mTOR抑制剂对头颈部鳞状细胞癌的抗肿瘤作用

2016-02-04

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Ann Oncol：MEK抑制剂trametinib对KRAS突变的非小细胞肺癌的II期临床研究

2015-08-01

科室
- - 订阅+
  - 更多科室
工具
服务